Operating Company Healthcare

SERB Pharmaceuticals

Paris, France

SERB Pharmaceuticals exists for critical medical moments. The company delivers life-saving medicines for rare and urgent conditions and operates end-to-end across 100+ countries to ensure essential medicines reach patients and clinicians wherever and whenever they’re needed.

Focus Areas
Specialty pharmaceuticals, Emergency care medicines / antidotes, Medical countermeasures (CBRN preparedness)
Website
serb.com

Tracked deals

3

3 tracked deals across 2020-2024.

Recent pace

0

0 tracked deals announced in the last 12 months.

Deal mix

Divestiture

2 divestiture · 1 addon

SERB Pharmaceuticals Acquisition Volume by Year

Last 3 years

Acquisition volume by year Annual acquisition counts for the last 3 years for SERB Pharmaceuticals. 1 2020 1 2023 1 2024

Supporting Data

Recent Transactions

  • SERB Pharmaceuticals Acquires RSDL Kit from Emergent BioSolutions for $75M
    July 31, 2024
    Buyer
    SERB Pharmaceuticals
    Target
    RSDL (Reactive Skin Decontamination Lotion) kit
    Seller
    Emergent BioSolutions Inc.
    Industry
    Medical Devices
    Location
    Maryland, United States
    Type
    Divestiture

    SERB Pharmaceuticals purchased the RSDL (Reactive Skin Decontamination Lotion) kit and related inventory, contracts and operations from Emergent BioSolutions for approximately $75 million, with an additional $5 million contingent milestone payment. The deal includes the Hattiesburg, Mississippi leased manufacturing facility and several site-based employees (who will join SERB), while Emergent's Winnipeg facility will continue to supply bulk lotion under a long-term supply agreement; Emergent said the divestiture supports debt reduction and portfolio rationalization.

  • SERB Pharmaceuticals Acquires Vistogard and Xuriden from Wellstat Therapeutics
    July 13, 2023
    Buyer
    SERB Pharmaceuticals, BTG Pharmaceuticals
    Target
    Vistogard, Xuriden
    Seller
    Wellstat Therapeutics
    Industry
    Pharmaceuticals
    Location
    Maryland, United States
    Type
    Divestiture

    SERB Pharmaceuticals has acquired the commercial rights to two medicines, Vistogard (uridine triacetate) and Xuriden (uridine triacetate), from Wellstat Therapeutics. The products will be sold in the United States by SERB’s US entity, BTG Pharmaceuticals; financial terms were not disclosed. The acquisition expands SERB’s portfolio in emergency care and rare diseases.

  • Laboratoires SERB (Charterhouse-backed) to acquire BTG Specialty Pharmaceuticals from Boston Scientific
    December 1, 2020
    Buyer
    Laboratoires SERB, Charterhouse Capital Partners LLP
    Target
    BTG Specialty Pharmaceuticals
    Seller
    Boston Scientific
    Industry
    Pharmaceuticals
    Location
    Pennsylvania, United States
    Type
    Addon

    Charterhouse Capital Partners–backed Laboratoires SERB has agreed to acquire BTG Specialty Pharmaceuticals from Boston Scientific. The deal expands SERB’s portfolio of emergency and critical‑care medicines (including CroFab, DigiFab and Voraxaze), strengthening its manufacturing capabilities and global commercial reach.

Related Acquisition Pages

Pharmaceuticals Buyers & Acquisitions 2 tracked deals by SERB Pharmaceuticals. Medical Devices Buyers & Acquisitions 1 tracked deal by SERB Pharmaceuticals. Acquisitions in Maryland 2 tracked deals by SERB Pharmaceuticals. Acquisitions in Pennsylvania 1 tracked deal by SERB Pharmaceuticals.

Related articles

Selling a company? Get in front of buyers like SERB Pharmaceuticals

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →